Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 10/01/2018
Entire Document
 


In re: Orexigen Therapeutics, Inc.

Debtor

  

Case No. 18-10518 (KG)

Reporting Period: August 1, 2018 - August 31, 2018

 

MOR - 1

Consolidated Schedule of Cash Receipts and Disbursements (1)

For the Period: August 1, 2018 - August 31, 2018

(Unaudited)

 

$ USD ‘000s

   August 1, 2018 -
August 31, 2018
    Cumulative
Since Filing
 

Beginning Cash Balance (Book)

   $ 36,874     $ 21,372  

Receipts

    

Operating Receipts

     —         64,422  

Miscellaneous Receipts

     1,487       70,549  
  

 

 

   

 

 

 

Total Receipts

     1,487       134,971  

Operating Disbursements

    

Payroll & Benefits / Contractors

     (554     (16,196

Inventory

     —         (4,406

Manufacturing and Logistics

     —         (133

Gross to Net Disbursements

     —         (36,451

Marketing / Commercial Operations

     (25     (15,998

Ordinary Course Professionals

     —         (637

Rent / Facilities / Equipment

     (3     (559

Insurance

     —         (279

IT / Utilities

     (44     (341

Regulatory and Compliance

     (7     (562

Other G&A

     (30     (927
  

 

 

   

 

 

 

Total Operating Disbursements

     (663     (76,491

Operating Cash Flow

     824       58,480  

Reorganization Costs

    

DIP Loan Interest and Fees

     —         (44,480

US Trustee Fees

     —         (371

Restructuring Professional Fees

     —         (3,564
  

 

 

   

 

 

 

Total Reorganization Costs

     —         (48,415

Total Disbursements

   $ (663   $ (124,906
  

 

 

   

 

 

 

Lender Professional Fees

     (266     (1,605

Net Cash Flow

   $ 558     $ 8,460  

DIP Draw—Cash

     —         7,600  
  

 

 

   

 

 

 

Ending Cash Balance (Book)

   $ 37,432     $ 37,432  

Notes:

 

(1)

The Schedule of Cash Receipts and Disbursements is presented on a book basis.